UCB, Others Sue 15 Generics Makers For Violating Vimpat Drug Patent
This article was originally published in PharmAsia News
Executive Summary
Glenmark, Ranbaxy Laboratories, Sun Pharma and other India drug makers are among 15 sued in a U.S. federal court for violating the patent of the epilepsy drug Vimpat (lacosamide) licensed to UCB.